Most Parkinson's symptoms stem from the loss or dysfunction of dopamine-producing neurons in a brain region involved in fine ...

If you bought a Freihofer's product over the last two months, you may have helped raise more than $18,000 to benefit the ...

A large longitudinal study found that pesticide exposure and caffeinated soda intake were linked to more severe motor ...

Jefferies analysts said on Tuesday that Ventyx could leverage its mid-stage data for VTX3232 to position the oral drug candidate as a treatment for other neurodegenerative diseases, including ...

Basel: Roche has announced its decision to proceed with Phase III development of prasinezumab, an investigational ...

Investing.com -- Ventyx Biosciences (NASDAQ: VTYX) stock was unchanged following the announcement of top-line data from its Phase 2a safety and biomarker trial evaluating VTX3232 in patients with ...

New research is bringing us closer to understanding how gut health may be tied to Parkinson’s disease, one of the world’s ...

Ventyx Biosciences has shared phase 2a data on a Parkinson’s disease prospect that has caught the eye of Sanofi. The readout shows the effect of VTX3232 on biomarkers, providing some of the data that ...

Roche and Prothena are advancing Prasinezumab to Phase 3 for Parkinson’s despite mixed Phase 2 results. Click here to read an ...

Cleveland Clinic Abu Dhabi, part of the M42 group, has successfully introduced continuous infusion therapy, a cutting-edge ...

Psilocybin therapy improved cognitive performance, reduced mood dysfunction, motor, and nonmotor symptoms in patients with Parkinson disease.

They were designed to treat diabetes, then prescribed for weight loss, and now—as researchers are finding—they might hold the ...